Drug Profile
Seasonal influenza virus vaccine quadrivalent - Sanofi Pasteur
Alternative Names: Efluelda; FluQuadri; FluQuadri Junior; Fluzone High-Dose Quadrivalent; Fluzone QIV ID; Fluzone QIV IM; Fluzone Quadrivalent; Fluzone Quadrivalent vaccine; Fluzone-HD; High dose quadrivalent influenza vaccine; High-Dose Influenza Vaccine Quadrivalent; IIV4-HD; Inactivated Quadrivalent Influenza Vaccine (Split Virion) influenza virus haemagglutinin; QIV; QIV - Sanofi pasteur; QIV-HD; Quadrivalent inactivated influenza virus vaccine; Quadrivalent influenza vaccine; Shenzhen quadrivalent influenza vaccine; Shz QIV; SP0178; Vaxigrip QIV IM; VaxigripTetraLatest Information Update: 04 Jan 2024
Price :
$50
*
At a glance
- Originator sanofi pasteur
- Developer Sanofi K.K.; Sanofi Pasteur
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 04 Jan 2024 No development reported - Phase-III for Influenza virus infections (In adolescents, In children, In infants, Prevention, In adults) in Vietnam (IM)
- 04 Jan 2024 No development reported - Phase-III for Influenza virus infections (In adolescents, In children, In the elderly, In infants, Prevention, In adults) in China (IM)
- 04 Jan 2024 No development reported - Phase-III for Influenza virus infections (In children, In infants, Prevention) in Greece (IM)